司特吉朗錠２５毫克

Land: Taiwan

Språk: kinesiska

Källa: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktiva substanser:

CINNARIZINE

Tillgänglig från:

嬌生股份有限公司 台北市大安區敦化南路二段319號4、5樓 (30814854)

ATC-kod:

N07CA02

Läkemedelsform:

錠劑

Sammansättning:

CINNARIZINE (0400000900) 25MG

Enheter i paketet:

瓶裝;;盒裝

Klass:

製　劑

Receptbelagda typ:

須由醫師處方使用

Tillverkad av:

JANSSEN KOREA LTD. 905 SANGSHIN-RI, HYANGNAM-EUP, HWASEONG-SI, KYUNGGI-DO, KOREA KR

Terapiområde:

cinnarizine

Terapeutiska indikationer:

噁心、眩暈、迷路障礙、暈動病、末梢血管循環障礙。

Produktsammanfattning:

註銷日期: 2015/01/20; 註銷理由: 有效期限已屆; 有效日期: 2013/01/21; 英文品名: STUGERON TABLETS 25MG

Bemyndigande status:

已註銷

Tillstånd datum:

1998-01-21

Bipacksedel

Company Core Data Sheet – STUGERON, 25 March 2009, Version 002
1
JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C.
COMPANY CORE DATA SHEET
STUGERON
®
CINNARIZINE
25 MARCH 2009
CONFIDENTIALITY STATEMENT
The information in this document contains trade secrets and commercial
information that are privileged or confidential and may
not be disclosed unless such disclosure is required by applicable law
or regulations. In any event, persons to whom the
information is disclosed must be informed that the information is
_privileged_
or
_confidential_
and may not be further disclosed by
them. These restrictions on disclosure will apply equally to
_all_
future information supplied to you which is indicated as
_privileged_
or
_confidential_
.
Company Core Data Sheet –
STUGERON, 25 March 2009, Version 002
2
1.
NAME OF THE MEDICINAL PRODUCT
STUGERON
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
25 mg cinnarizine per tablet.
75 mg cinnarizine per capsule.
75 mg cinnarizine per ml oral drops.
For excipients, see Section 6.1.
3.
PHARMACEUTICAL FORM
Tablets.
Capsules.
Oral drops, suspension.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
•
Maintenance therapy for symptoms of labyrinthine disorders, including
vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting.
•
Prophylaxis of motion sickness.
•
Prophylaxis of migraine.
•
Maintenance therapy for symptoms of cerebrovascular origin, including
dizziness, ear buzzing (tinnitus), vascular headache, unsociability
and
irritability disorders, loss of memory and lack of concentration.
•
Maintenance therapy for symptoms of peripheral circulatory disorders,
including
Raynaud’s
phenomenon,
acrocyanosis,
intermittent
claudication,
trophic
disturbances,
trophic
and
varicose
ulcers,
paraesthesia, nocturnal cramps, cold extremities.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
_Cerebral circulatory disorders: _
1 tablet of 25 mg t.i.d. or 1 capsule of 75 mg daily, or 3 x 8 drops
(= 3 x
24 mg) daily.
_Peripheral circulatory disorders: _
Company Core Data She